Intraocular Inflammation Following Intravitreal Faricimab: Insights from Five Bilateral Cases

Purpose: To evaluate the incidence of intraocular inflammation (IOI) after intravitreal (IVT) faricimab injection. Methods: A retrospective observational study was performed of all patients who received IVT faricimab injections at NHS Highland between January 2023 and June 2024 and subsequently developed IOI. Results: IOI was seen in 11 eyes of 6 patients after faricimab injection. All aqueous and vitreous cultures were negative. Among patients who received bilateral faricimab injections, the incidence of IOI was 8.5% (5/59). Four eyes experienced a vision loss of 11.5 ± 8.6 Early Treatment Diabetic Retinopathy Study letters. Cases were characterized by a delayed onset of subacute symptoms after injection, keratic precipitates, and elevated intraocular pressure. Conclusions: Although the overall incidence of faricimab-related IOI is low, our findings highlight the need for increased vigilance in patients receiving bilateral faricimab injections.